Multidimensional assessment of patient condition and mutational analysis in peripheral blood, as tools to improve outcome prediction in myelodysplastic syndromes: A prospective study of the Spanish MDS group. Issue 9 (19th July 2017)

• Record Type: Journal Article
• Authors: Ramos, Fernando; Robledo, Cristina; Pereira, Arturo; Pedro, Carmen; Benito, Rocío; de Paz, Raquel; del Rey, Mónica; Insunza, Andrés; Tormo, Mar; Díez‐Campelo, María; Xicoy, Blanca; Salido, Eduardo; Sánchez‐del‐Real, Javier; Arenillas, Leonor; Florensa, Lourdes; Luño, Elisa; del Cañizo, Consuelo; Sanz, Guillermo F.; María Hernández‐Rivas, Jesús
• Is Part Of: American journal of hematology. Volume 92:Issue 9(2017:Sep.)
• Page Start: E534
• Page End: E541
• Publication Date: 2017-07-19
• Subjects: Hematology -- Periodicals; 616.15
• DOI: 10.1002/ajh.24813
• Languages: English
• ISSNs: 0361-8609

Abstract

Abstract: The International Prognostic Scoring System and its revised form (IPSS‐R) are the most widely used indices for prognostic assessment of patients with myelodysplastic syndromes (MDS), but can only partially account for the observed variation in patient outcomes. This study aimed to evaluate the relative contribution of patient condition and mutational status in peripheral blood when added to the IPSS‐R, for estimating overall survival and the risk of leukemic transformation in patients with MDS. A prospective cohort (2006–2015) of 200 consecutive patients with MDS were included in the study series and categorized according to the IPSS‐R. Patients were further stratified according to patient condition (assessed using the multidimensional Lee index for older adults) and genetic mutations (peripheral blood samples screened using next‐generation sequencing). The change in likelihood‐ratio was tested in Cox models after adding individual covariates. The addition of the Lee index to the IPSS‐R significantly improved prediction of overall survival [hazard ratio (HR) 3.02, 95% confidence interval (CI) 1.96–4.66, P < 0.001), and mutational analysis significantly improved prediction of leukemic evolution (HR 2.64, 1.56–4.46, P < 0.001). Non‐leukemic death was strongly linked to patient condition (HR 2.71, 1.72–4.25, P < 0.001), but not to IPSS‐R score ( P = 0.35) or mutational status ( P = 0.75). Adjustment for exposure to disease‐modifying therapy, evaluated as a time‐dependent covariate, had no effect on the proposed model's predictive ability. In conclusion, patient condition, assessed by the multidimensional Lee index and patient mutational status can improve the prediction of clinical outcomes of patients with MDS already stratified by IPSS‐R.